CD8A and neoplasm: Regarding specific mechanisms, SPP1hi-TAMs can inhibit the anti-tumor function of CD8+ T cells through the adenosine-A2AR pathway (28); while Pygo2 inhibitors can reverse immune checkpoint inhibitor resistance by enhancing the infiltration of cytotoxic T lymphocytes in tumor tissues (195).